Bird & Bird grows its Corporate group with the appointment of James Baillieu as partner in London

10-2018

International law firm Bird & Bird today expands its Corporate practice group with the appointment of James Baillieu as a partner in London.

James joins from Norton Rose Fulbright where he was Of Counsel. He also previously worked at Covington & Burling in London and Conyers Dill & Pearman in the British Virgin Islands. James advises corporates, investment banks, private equity firms and venture capital funds on complex cross-border transactions including mergers and acquisitions, joint ventures, private equity, growth equity and venture capital investments and corporate reorganisations. He has particular expertise advising clients in the life sciences, healthcare and technology sectors.  

At Bird & Bird, James will work closely with the Life Sciences & Healthcare and Tech & Comms sector groups, drawing on his experience to advise clients in the life sciences, healthcare and technology sectors.  

Matt Bonass, Head of Bird & Bird's London Corporate practice says: "We are delighted to welcome James to Bird & Bird. His appointment is a key part of our international Corporate practice strategy: to provide corporate expertise to new and existing clients in the firm's sector groups. James will work closely with other corporate partners across the firm's international offices and advise clients specifically on transactions within the life sciences, healthcare and technology areas."

Mark Hilton, Co-Head of Bird & Bird's Life Sciences & Healthcare sector group comments: "Clients in this sector are increasingly seeking specialist guidance around corporate investments and transactions. James' comprehensive experience advising on these matters in the life sciences and healthcare sectors will boost the team's capabilities in London and across the firm. We look forward to welcoming him to the team."  

James adds: "I am delighted to join Bird & Bird. The firm's strong sector focus and international presence will provide me with the ideal platform to both support the Corporate team and to advise clients in the life sciences, healthcare and the technology sectors on their strategic corporate transactions. I'm very much looking forward to working with my new colleagues worldwide."